News

We will keep you informed with the latest news

MT awarded NCI SBIR Phase II grant

11/01/2022

 

Molecular Theranostics has been awarded a two-year, $2 million National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Award to study the magnetic imaging efficacy of MT218 in prostate cancer patients and safety, after successfully completing a clinical trial in 30 healthy volunteers.

Funded by the NIH, the award supports a diverse portfolio of startups and small businesses across technology areas and markets to stimulate technological innovation, meet Federal research and development (R&D) needs, and increase commercialization to transition R&D into impact.

IMG-8169.JPG

MT Attend BIO Investor Forum 2019

10/22/2019

Molecular Theranostics CEO Yajuan Li, Ph.D. presenting at Bio Investor Forum in San Francisco, California

Topic is "Targeted peptide based agents for tumor precise imaging"

VIEW MORE
IMG-8171.JPG

MT CEO Interview with Proactive 

10/22/2019

"Molecular Theranostics LLC CEO Yajuan Li spoke with Proactive at the 2019 BIO Investor Forum in San Francisco. "

VIEW MORE